Secretome Therapeutics raised $30 million to advance STM-01, a neonatal cardiac progenitor cell therapy in clinical development for the treatment of Duchenne muscular dystrophy-associated cardiomyopathy, a rare and fatal genetic disease in which cardiac complications are among the leading causes of death.
